Northwestern University Human Resources
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1851-01-28
- Employees
- 5K
- Market Cap
- -
A Universal Medication Schedule to Promote Adherence to Complex Drug Regimens
Not Applicable
Completed
- Conditions
- Adherence
- Interventions
- Behavioral: EHR + (Text or Portal)
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 677
- Registration Number
- NCT02820753
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Project FACTS (Fidelity Accuracy: Comparing Three Strategies)
Not Applicable
Completed
- Conditions
- Assess Fidelity to Cognitive-behavioral Therapy for Youth
- Interventions
- Behavioral: Behavioral RehearsalBehavioral: Self-reportBehavioral: Chart-Stimulated Recall
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 126
- Registration Number
- NCT02820623
Designing a Programming Language for Patient-Oriented Prescriptions
Completed
- Conditions
- Programming LanguagesPatients
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 56
- Registration Number
- NCT02820168
- Locations
- 🇺🇸
Northwestern Medicine Clinics, Chicago, Illinois, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase 1
Terminated
- Conditions
- Recurrent Adult Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1Recurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: DasatinibOther: Laboratory Biomarker AnalysisBiological: NivolumabOther: Pharmacological Study
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 1
- Registration Number
- NCT02819804
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Patient Comfort During Dermatologic Procedures
Not Applicable
Completed
- Conditions
- AnxietyPain
- Interventions
- Procedure: Stress BallProcedure: Hand-holding
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 135
- Registration Number
- NCT02816996
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Phase 1
Completed
- Conditions
- Stage 0a Bladder Urothelial CarcinomaStage I Bladder CancerRecurrent Bladder CarcinomaStage 0is Bladder Urothelial Carcinoma
- Interventions
- Biological: BCG SolutionOther: Laboratory Biomarker AnalysisBiological: PembrolizumabOther: Pharmacological Study
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT02808143
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Early Phase 1
Withdrawn
- Conditions
- Polycythemia VeraThrombocytopeniaPrimary MyelofibrosisMyelofibrosis
- Interventions
- Procedure: Bone Marrow Aspiration and BiopsyOther: Laboratory Biomarker AnalysisBiological: Siltuximab
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT02805868
IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression
Not Applicable
Completed
- Conditions
- DepressionAnxiety
- Interventions
- Behavioral: IntelliCareBehavioral: Hub App with the Recommender SystemBehavioral: Coaching
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 301
- Registration Number
- NCT02801877
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Phase 2
Completed
- Conditions
- Malignant GliomaRecurrent Glioblastoma
- Interventions
- Biological: DurvalumabOther: Laboratory Biomarker AnalysisProcedure: Surgical ProcedureBiological: Tremelimumab
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 36
- Registration Number
- NCT02794883
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Testing a Medication Risk Communication and Surveillance Strategy: The EMC2 Trial
Not Applicable
Completed
- Conditions
- High-risk Medications
- Interventions
- Behavioral: EMC2 Strategy
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 1005
- Registration Number
- NCT02785458
- Locations
- 🇺🇸
Near North Health Services Corporation, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath